|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen and his colleagues perform a metaanalsysis on published clinical trial data on the diabetes drug Avandia and conclude that it may be associated with a 43% increase in heart attack risk for some patients.
We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinicaltrials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our metaanalysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.
|home spotlight commentary research events news about contact links archives|